ESSA Pharma Inc. held a special meeting of security holders on October 3, 2025, to vote on its acquisition by XenoTherapeutics Inc., with the meeting concluding after requisite approvals were obtained for the arrangement and liquidation resolutions. The meeting was held online, and voting results will be posted on the company's SEDAR+ profile. The acquisition is proceeding based on a Business Combination Agreement, with the meeting's success paving the way for the transaction.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.